Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Routine +

Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 4Q26

Stonegate updates coverage on Burcon Nutrascience Corporation (BU) 4Q26

By The Northwire Desk — AI Analysis Jun 26, 2026 · 16:21 BU · 1.95 BURCON NUTRASCIENCE CORPORATION J
Executive Summary
  • Stonegate Capital Partners updates coverage on Burcon's FY26 4Q results and early FY27 commercial traction.
  • Commercial production officially launched across core protein lines (Peazazz, Puratein C, and FavaPro) in FY26.
  • 4Q26 revenue reached $0.83M CAD, up from $0.74M in 3Q26.
  • Current-quarter sales are tracking toward approximately 50% sequential growth based on April/May activity.
  • Daily production output set a new record, running roughly 60% above January-March levels.
  • Customer traction has broadened to 30+ purchasing customers and 200+ active projects across pea, canola, and fava applications.
  • Margin expansion is expected to stem from improved facility utilization, a steadier production cadence, and the removal of start-up costs from the run-rate cost structure.
  • Funding status stands at $6.9M completed and $3.0M undrawn, with management targeting $10M in CY26 sales.
  • The company is moving into a utilization ramp mode to achieve better fixed-cost absorption at the Galesburg site.
Material Impact
  • The news is a routine commercial update confirming the $10M CY26 sales target and highlighting sequential sales growth and production records.
  • It does not contain genuinely new market-relevant information that would re-rate the business. The operational progress was already telegraphed in prior updates (e.g., 50% QoQ sales growth, production records).
  • The stock's -16.6% drop into the FY26 earnings print suggests the market was focused on the $14.3M net loss and negative working capital. This update does not materially alter that negative financial narrative.
BU · Price
Company Overview
  • Burcon Nutrascience is a plant protein technology company that commercialized its Galesburg, Illinois production facility in FY26.
  • Core products include Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein.
  • The company is transitioning from technology development to commercial execution, leveraging a manufacturing partnership with RE ProMan LLC.
  • Target markets include ready-to-mix beverages, nutrition bars, snacks, baked goods, and plant-based foods.
Read the original news release →

More from BURCON NUTRASCIENCE CORPORATION J

Jun 24, 2026 · 16:12

494% revenue jump overshadowed by $14.3M loss, negative equity, and costly insider debt; liquidity a red flag.

Earnings Jun 16, 2026 · 08:01

Commercial scaling accelerates, but negative equity and explicit capital calls keep the risk/reward skewed to the downside.

Production / Operations Apr 20, 2026 · 08:01

Burcon NutraScience Ramps Production Amidst Cash Burn Concerns

Production / Operations Feb 27, 2026 · 20:10

Burcon closes $2.75M second tranche of placement

Financings Feb 27, 2026 · 16:38

Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million

Financings Feb 20, 2026 · 15:34

Burcon Announces Results of Shareholder Meeting

Financings